secwatch.observer — SEC 8-K summary
======================================

Issuer:     Sensei Biotherapeutics, Inc. (SNSE)
CIK:        0001829802
Form:       8-K
Filed at:   2026-06-18T21:13:03+00:00
Accession:  0001193125-26-276093
Event type: other_material
Sentiment:  negative
Materiality: 0.70
Item codes: 1.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Faeth Therapeutics enters $150M ATM equity facility; Series B preferred converts to common
--------------------------------------------------------------------------------

- Entered Sales Agreement with TD Securities for at-the-market offering of common stock up to $150M.
- Agent TD Securities receives up to 3% commission; shares sold at market prices from time to time.
- Series B Non-Voting Convertible Preferred (24,435.6 shares) automatically converted into 24,435,594 common shares on June 15.
- Post-conversion, common shares outstanding increase to 25,778,754 as of June 15, 2026.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1829802/000119312526276093/0001193125-26-276093-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1829802/000119312526276093/d82589d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-276093

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer